Association of triglycerides to high-density lipoprotein cholesterol ratio to identify future prediabetes and type 2 diabetes mellitus: over one-decade follow-up in the Iranian population.
Dysglycemia
High-density lipoprotein cholesterol
Prediabetes
Ratio
Triglycerides
Type 2 diabetes mellitus
Journal
Diabetology & metabolic syndrome
ISSN: 1758-5996
Titre abrégé: Diabetol Metab Syndr
Pays: England
ID NLM: 101488958
Informations de publication
Date de publication:
02 Feb 2023
02 Feb 2023
Historique:
received:
29
08
2022
accepted:
27
01
2023
entrez:
3
2
2023
pubmed:
4
2
2023
medline:
4
2
2023
Statut:
epublish
Résumé
To determine the association between triglyceride to high-density lipoprotein cholesterol ratio (TG/HDL-C) for identifying subjects at risk of incident prediabetes and type 2 diabetes mellitus (T2DM). In 5064 subjects (men = 2247) aged ≥ 20 years, using Cox proportional hazards regression analyses, the associations of TG/HDL-C with incident prediabetes and T2DM were examined among normoglycemic men and women. Furthermore, the association of this lipid ratio with incident T2DM was also assessed among prediabetic subjects (n = 1414). The multivariable analyses were adjusted for age, body mass index, waist-to-height ratio, wrist circumference, systolic blood pressure, family history of T2DM, education level, history of cardiovascular diseases, and fasting plasma glucose (FPG). During a median follow-up of 11.2 years, 2140 new cases of prediabetes (men = 1070) and 360 incident T2DM (men = 152) were identified among normoglycemic individuals. In the prediabetic population, 574 new cases of T2DM (men = 252) were developed. Among the whole population, compared to the first quartile (reference), higher quartiles of TG/HDL-C were significantly associated with higher risks of incident prediabetes and T2DM among normoglycemic individuals and incident T2DM in the prediabetic population (all P for trend < 0.001). The corresponding hazard ratios (HRs) and 95% confidence intervals (CIs) for the fourth quartiles were 1.37(1.20-1.58), 1.92(1.34-2.75), and 1.57(1.22-2.01), respectively. The sex-stratified analyses demonstrated similar significant associations in both sexes; however, TG/HDL-C lost its association with incident T2DM among prediabetic men. Among the normoglycemic population, 1 unit increase in TG/HDL-C was significantly associated with incident prediabetes and T2DM [1.02(1.00-1.03) and 1.06(1.03-1.08), respectively]. The corresponding value for incident T2DM in prediabetic individuals was 1.01(1.00-1.03). In a subgroup population having insulin data (n = 2897), the associations between TG/HDL-C and incident prediabetes and T2DM among normoglycemic individuals generally persisted even after replacing FPG with an index of insulin resistance (IR), i.e., homeostasis model assessment of IR (HOMA-IR) in the adjusted model. In conclusion, in the normoglycemic population, the increasing value of TG/HDL-C was unfavorably associated with incident prediabetes and T2DM, especially among women. Similarly, TG/HDL-C was associated with incident T2DM in prediabetic individuals. Generally, we found that the correlation between TG/HDL-C and different states of dysglycemia is independent of HOMA-IR.
Sections du résumé
BACKGROUND
BACKGROUND
To determine the association between triglyceride to high-density lipoprotein cholesterol ratio (TG/HDL-C) for identifying subjects at risk of incident prediabetes and type 2 diabetes mellitus (T2DM).
METHODS
METHODS
In 5064 subjects (men = 2247) aged ≥ 20 years, using Cox proportional hazards regression analyses, the associations of TG/HDL-C with incident prediabetes and T2DM were examined among normoglycemic men and women. Furthermore, the association of this lipid ratio with incident T2DM was also assessed among prediabetic subjects (n = 1414). The multivariable analyses were adjusted for age, body mass index, waist-to-height ratio, wrist circumference, systolic blood pressure, family history of T2DM, education level, history of cardiovascular diseases, and fasting plasma glucose (FPG).
RESULTS
RESULTS
During a median follow-up of 11.2 years, 2140 new cases of prediabetes (men = 1070) and 360 incident T2DM (men = 152) were identified among normoglycemic individuals. In the prediabetic population, 574 new cases of T2DM (men = 252) were developed. Among the whole population, compared to the first quartile (reference), higher quartiles of TG/HDL-C were significantly associated with higher risks of incident prediabetes and T2DM among normoglycemic individuals and incident T2DM in the prediabetic population (all P for trend < 0.001). The corresponding hazard ratios (HRs) and 95% confidence intervals (CIs) for the fourth quartiles were 1.37(1.20-1.58), 1.92(1.34-2.75), and 1.57(1.22-2.01), respectively. The sex-stratified analyses demonstrated similar significant associations in both sexes; however, TG/HDL-C lost its association with incident T2DM among prediabetic men. Among the normoglycemic population, 1 unit increase in TG/HDL-C was significantly associated with incident prediabetes and T2DM [1.02(1.00-1.03) and 1.06(1.03-1.08), respectively]. The corresponding value for incident T2DM in prediabetic individuals was 1.01(1.00-1.03). In a subgroup population having insulin data (n = 2897), the associations between TG/HDL-C and incident prediabetes and T2DM among normoglycemic individuals generally persisted even after replacing FPG with an index of insulin resistance (IR), i.e., homeostasis model assessment of IR (HOMA-IR) in the adjusted model.
CONCLUSIONS
CONCLUSIONS
In conclusion, in the normoglycemic population, the increasing value of TG/HDL-C was unfavorably associated with incident prediabetes and T2DM, especially among women. Similarly, TG/HDL-C was associated with incident T2DM in prediabetic individuals. Generally, we found that the correlation between TG/HDL-C and different states of dysglycemia is independent of HOMA-IR.
Identifiants
pubmed: 36732786
doi: 10.1186/s13098-023-00988-0
pii: 10.1186/s13098-023-00988-0
pmc: PMC9893691
doi:
Types de publication
Journal Article
Langues
eng
Pagination
13Subventions
Organisme : Shahid Beheshti University of Medical Sciences
ID : No.2-43002896
Organisme : The National Research Council of the Islamic Republic of Iran
ID : 121
Informations de copyright
© 2023. The Author(s).
Références
PLoS One. 2019 Jan 31;14(1):e0211070
pubmed: 30703129
J Diabetes Complications. 2019 Feb;33(2):118-122
pubmed: 30522790
Diabetes Care. 2022 Jan 1;45(Suppl 1):S17-S38
pubmed: 34964875
J Pediatr Endocrinol Metab. 2020 May 24;33(6):777-784
pubmed: 32447329
J Clin Endocrinol Metab. 2013 Feb;98(2):777-84
pubmed: 23341488
Diabetes Res Clin Pract. 2017 Jun;128:40-50
pubmed: 28437734
Front Endocrinol (Lausanne). 2022 Jul 18;13:947157
pubmed: 35923622
Horm Metab Res. 2017 Jul;49(7):542-549
pubmed: 28597452
Am J Cardiol. 2012 Jun 15;109(12):1749-53
pubmed: 22449634
Diabet Med. 2017 Jan;34(1):69-78
pubmed: 26606421
Endocrinol Metab Clin North Am. 2021 Sep;50(3):369-385
pubmed: 34399951
Acta Diabetol. 2018 Oct;55(10):1067-1074
pubmed: 30066042
Lipids Health Dis. 2016 Jun 07;15:104
pubmed: 27267043
Eur J Public Health. 2011 Oct;21(5):554-9
pubmed: 20534689
J Cardiol. 2018 Jan;71(1):8-9
pubmed: 29033056
Nutr Metab Cardiovasc Dis. 2022 Feb;32(2):318-329
pubmed: 34953633
Nutr Metab Cardiovasc Dis. 2022 Aug;32(8):1872-1879
pubmed: 35753859
Diabetes Care. 2015 Apr;38(4):628-36
pubmed: 25592196
J Clin Hypertens (Greenwich). 2010 Jan;12(1):51-8
pubmed: 20047632
Diabet Med. 2017 Feb;34(2):245-252
pubmed: 26996519
Diabetes Res Clin Pract. 2020 May;163:108150
pubmed: 32305400
Int J Mol Sci. 2014 Apr 11;15(4):6184-223
pubmed: 24733068
Int J Endocrinol. 2021 Jul 08;2021:9949579
pubmed: 34306073
PLoS One. 2014 Jul 16;9(7):e102563
pubmed: 25029368
Cardiovasc Diabetol. 2011 Oct 17;10:93
pubmed: 22004541
Diabetes Care. 2008 Jan;31(1):96-8
pubmed: 17921357
J Diabetes Complications. 2022 Jul;36(7):108231
pubmed: 35718599
Diabetes Res Clin Pract. 2019 Nov;157:107843
pubmed: 31518657
Cardiovasc Diabetol. 2021 Sep 9;20(1):183
pubmed: 34503545
Diabetes Metab Res Rev. 2016 Sep;32(6):572-80
pubmed: 26663847
J Diabetes. 2019 Mar;11(3):183-192
pubmed: 30091266
Pathophysiology. 2022 Jul 17;29(3):374-382
pubmed: 35893599
Lipids Health Dis. 2010 Aug 17;9:85
pubmed: 20712907
Front Pharmacol. 2015 Oct 31;6:258
pubmed: 26582989
Lipids Health Dis. 2020 Jun 2;19(1):121
pubmed: 32487177
Am J Physiol Endocrinol Metab. 2008 Jan;294(1):E15-26
pubmed: 17957034
Acta Diabetol. 2015 Oct;52(5):905-15
pubmed: 25794879
Lipids Health Dis. 2019 Jun 1;18(1):130
pubmed: 31153374